Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease—A Pediatric Perspective

Andrea Grund¹,²*, Manish D. Sinha³, Dieter Haffner¹,² and Maren Leifheit-Nestler¹,²*

¹Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School Children’s Hospital, Hanover, Germany, ²Paediatric Research Centre, Hannover Medical School, Hanover, Germany, ³Department of Paediatric Nephrology, King’s College London, Evelina London Children’s Hospital, London, United Kingdom

Cardiovascular diseases (CVD) are a hallmark in pediatric patients with chronic kidney disease (CKD) contributing to an enhanced risk of all-cause and CV morbidity and mortality in these patients. The bone-derived phosphaturic hormone fibroblast growth factor (FGF) 23 progressively rises with declining kidney function to maintain phosphate homeostasis, with up to 1,000-fold increase in patients with kidney failure requiring dialysis. FGF23 is associated with the development of left ventricular hypertrophy (LVH) and thereby accounts to be a CVD risk factor in CKD. Experimentally, FGF23 directly induces hypertrophic growth of cardiac myocytes in vitro and LVH in vivo. Further, clinical studies in adult CKD have observed cardiotoxicity associated with FGF23. Data regarding prevalence and determinants of FGF23 excess in children with CKD are limited. This review summarizes current data and discusses whether FGF23 may be a key driver of LVH in pediatric CKD.

Keywords: fibroblast growth factor 23, left ventricular hypertrophy, children, chronic kidney disease - mineral and bone disease, chronic kidney disease

INTRODUCTION

Chronic kidney disease (CKD) is a significant global health issue and defined as gradual loss of kidney function ultimately leading to irreversible kidney damage (1). CKD patients present a high risk for cardiovascular events. Fifty percent which remain the predominant cause of patients with CKD stage 4 and 5 develop cardiovascular diseases (CVD), which cause of death with 40% mortality rate (2). The cardiorenal syndrome (CRS) type 4 reflects the complex relationship between primary CKD and resultant CVD (3, 4). Left ventricular hypertrophy (LVH), cardiac fibrosis and vascular diseases remain the most common cardiac abnormalities in CRS 4, with 90% of adult patients with kidney failure developing LVH (5, 6). The primary causes of cardiac-associated death in these adults on haemodialysis are stroke, congestive heart failure, myocardial infarction and cardiac arrest (7, 8). Childhood CKD is also associated with amplified cardiovascular (CV) morbidity and mortality both during childhood with progressive worsening in those with childhood-onset CKD become young adults (7–9). The severity of CVDs in CKD patients is aggravated by the mineral bone disorder of CKD, called Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Thus, CKD-MBD is a CKD-specific cardiovascular risk factor and displays changes in mineral metabolism parameters including phosphate, calcium, parathyroid hormone (PTH), calcitriol...
(1,25-dihydroxyvitamin D3, or 1,25D), and fibroblast growth factor 23 (FGF23) (10). In children with CKD impaired bone architecture may result in bone pain and deformities, short stature, fractures and ectopic calcifications. In children, LVH is the commonest CV abnormality with reported prevalence between 17 and 55%, increasing prevalence with worsening GFR (11–14). As LVH and its progression are associated with adverse CV outcomes in patients with CKD (15), it remains important to understand additional risk factors. The present narrative review focusses on FGF23, a bone-derived phosphaturic hormone regulating renal phosphate homeostasis, in the development of LVH in pediatric CKD and summarizes recent clinical literature in this field.

**GENERAL MECHANISMS OF CVD IN CKD**

Mainly, there are two different processes involved in the development of CVD. As a response to mechanical or hemodynamic overload, a remodeling process leads to hypertrophy of the left ventricle (LV) (16). There is evidence, that LV dysfunction in children with CKD predisposes them to LVH (17). Pressure overload resulting from prolonged hypertension leads to concentric hypertrophy, whereas eccentric hypertrophy is a cause of volume overload due to e.g., aortic and mitral valve insufficiency (18). These two different mechanisms induce distinct patterns of cardiac myocyte contractile protein (sarcomere) formation. New sarcomeres are added in parallel with relative increase in the width of the myocytes during pressure-induced concentric LVH. The pronounced increase in wall thickness with only little expansion of the LV cavity is a direct effect of the myocyte growth. During eccentric hypertrophy the LV cavity together with wall thickness is increased. Here, sarcomeres are added in series producing longitudinal growth of cardiac myocytes. Importantly, when myocytes elongated only in length without an increase in diameter, the LV dilates. Both, pressure and volume overload trigger the activation of multiple signaling pathways leading to myocardial remodeling (18). In CKD patients, these mechanisms can be activated independently, since here numerous humoral factors are altered *a priori*. To make matters worse, different hemodynamic stimuli e.g., hypertension, arterial stiffness, volume expansion, and anemia can occur simultaneously in CKD, resulting in distinct alterations of LV geometry (19). Hypertrophy of the LV becomes maladaptive with decreased capillary density, arrhythmia, and myocardial fibrosis leading to myocyte death causing diastolic and systolic dysfunction. The activation of the renin–angiotensin–aldosterone system (RAAS) is also known to induce LVH (20, 21). FGF23 can stimulate RAAS directly by inhibiting renal Angiotensin Converting Enzyme 2 (ACE2), thus inhibiting its vasodilatory and hypotensive properties resulting in promotion of vasoconstrictive and inflammatory effects of angiotensin II (22–24). Vice versa, FGF23 expression may also be stimulated by RAAS activation (25). Interestingly, FGF23 blunts the protective effects of angiotensin receptor blocker (ARBs) on the kidney and mitigates the expression of anti-inflammatory genes in experimental renal failure (26). Since, hypertension is one of the most common comorbidities in CKD patients, FGF23-mediated activation of RAAS may play an important role in hypertension in CKD.

Vascular injury is promoting CVD as well. Changes in vascular tissue, leading to atherosclerotic and arteriosclerotic alterations and/or vascular calcification, are very common in CKD. Plaque and atheroma formation during arteriosclerosis start with accumulation of macrophages in the vascular intima followed by aggregation of lipids, different fibers of collagen and smooth muscle cells. At the same time, calcification with the development of atherosclerotic lesions at the intima occurs causing stenosis and local closures of the artery. Circulating endothelial progenitor cells (EPCs) contribute to angiogenetic processes where they are recruited to the heart vessels after injury or damage. Studies show a reduced number of EPCs with impaired function in CVD (27).

In arteriosclerosis, the process of arterial stiffening and arterial calcification results in arteries with thicker intima and media, which affects their elasticity. The increased wall thickness together with a lumen enlargement, resulting in higher systolic blood pressure and arterial stiffening, characterize the vascular remodeling processes during arteriosclerosis. The main consequences of arterial stiffening are LVH and an altered coronary perfusion (28).

Over the past decade, vascular calcification in combination with chronic inflammation have come into focus as another risk factor for CVD in CKD, driving disease progression particularly in children on chronic dialysis (29). In combination with oxidative stress, inflammation is implicated in the progression of CKD due to increased production of pro-inflammatory cytokines such as C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) with IL6 and TNF-α being strong inducers of vascular calcification (30). In the Modification of Diet in Renal Disease (MDRD) study and in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) higher CRP levels have been independently linked to CVD prevalence in diabetic and non-diabetic kidney disease (31, 32). Mechanistically, CRP has been shown to enhance transdifferentiation of vascular smooth muscle cells (VSMC) via an Fc fragment of IgG receptor IIa (FCGR2A)-dependent activation of oxidative stress (33). Loss of VSMCs quiescent phenotype and their transdifferentiation into osteoblastic-like cells with increased mineralized matrix secretion lead to the progression of vascular calcification (34).

The pro-inflammatory marker IL-6 is involved in the development of atherosclerotic lesions by recruiting inflammatory cells. Circulating plasma level of IL-6 were elevated in a cohort of stable haemodialysis patients enrolled in the HEMO study suggesting IL-6 to be a strong predictor of CV and all-cause death (35, 36). Furthermore, in a recent clinical study measuring IL-6 in patients with coronary artery calcification in CKD, IL-6 was found to be a strong and independent predictor of CV and all-cause death (37).

TNF-α is induced by inflammatory stimuli and stimulates the immune response. It was shown to be upregulated in kidney disease and LVH in patients receiving dialysis (38). Increased level of circulating TNF-α are observed in myocardial
dysfunction and fibrosis and it is thought to be involved in the development of atherosclerosis by impairing endothelial function (39). Despite these data, currently there is no therapy available for the treatment of inflammation to decrease CV calcification in those with CKD. Recently, using an experimental CKD model, Singh et al. reported that activation of FGFR4 and PLCγ/calcineurin/NFAT signaling by FGF23 in the liver stimulated an inflammatory response (40). Blockade of FGFR receptor 4 (FGFR4) resulted in reduced circulating CRP levels. Since FGFR4 is expressed in a wide range of tissue, this FGFR isoform might be a promising target for clinical intervention.

**CVD IN PEDIATRIC CKD**

In children, LVH develops early in mild and moderate chronic renal insufficiency and exacerbates with kidney failure requiring dialysis (9, 11, 41). Children with CKD show the same risk factors that predict the development of cardiac hypertrophy as adults, although the duration of the “abnormality” is shorter. Importantly however, in contradistinction to adults, children do not have long-standing hypertension and other major co-morbidities including diabetes and smoking. Amongst modifiable risk associations for LVH in children, anemia, increasing ponderosity, hypertension and treatment with antihypertensive medications that do not target RAAS e.g., vasodilators, have been reported previously (42–44). Numerous studies have observed a correlation of increased PTH levels and the progression of LVH in children with CKD stages 2–4 with PTH having a direct effect on cardiac myocytes (45, 46). Thus, Bakkaloglu et al. show in the IPPN cohort for children with CKD an increased risk for developing LVH of over 70% (47).

Endothelial dysfunction (ED) measured by impaired endothelium-dependent flow-mediated dilation (FMD) is observed in children with advanced kidney failure, on chronic dialysis and after renal transplantation (48, 49). Nitric oxide deficiency and oxidative stress are discussed as cause and consequence of ED (50, 51). In addition, vascular abnormalities display a high prevalence in pediatric CKD. Medial vascular calcification due to its association with increased vascular stiffening and cardiac workload, poor coronary perfusion, and sudden cardiac death, is responsible for the high risk for CV mortality even in young adults with CKD and this risk may be comparable to the older people in the general population (52, 53). The association between CKD and accelerated vascular aging is evident and discussed intensively, but so far little is known about the underlying molecular mechanisms (54–56). A dysregulated calcium (Ca) and phosphate (P) metabolism accelerate vascular calcification in CKD that is promoted by the death of vascular smooth muscle cells and osteogenic differentiation (57, 58). Major physiological regulators of Ca and P metabolism are FGF23 and its co-receptor α-Klotho as well as PTH, 25-hydroxyvitamin D (25OHD) and calcitriol (59).

Recently, a focus on uremic toxins has been evaluated to account for vascular calcification and fibrosis. Indoxyl sulfate (IS), a metabolite of the tryptophan metabolism that accumulates in the plasma during kidney failure, for example correlates with congestive heart failure in patients with CKD (60). IS induces the expression of runt-related transcription factor 2 (Runx2) and osteopontin (OPN) and activates the PI3K/Akt/NF-κB pathway, all of them participating in the differentiation of vascular smooth muscle cells (VSMCs) from a contractile to osteogenic phenotype thereby promoting vascular calcification in CKD (61–63). Furthermore, IS has pro-hypertrophic, pro-fibrotic, and pro-inflammatory properties and stimulates hypertrophy in neonatal rat cardiomyocytes and collagen synthesis in neonatal rat cardiac fibroblasts via activation of MAP kinases and NF-κB pathways (64).

**FGF23 IN CKD**

FGF23 physiologically binds to the FGF receptors (FGFR) 1/α-Klotho complex in the kidney to mediate downregulation of sodium-dependent phosphate co-transporters (NaPi2a and NaPi2c) that results in decreased tubular phosphate reabsorption and finally lower serum phosphate levels (Figure 1). In early stages of CKD, the increased level of FGF23 go along with unchanged level of phosphate and PTH (65, 66). The advanced progression of CKD results in phosphate retention that increases FGF23 levels further on (67, 68). At the same time, PTH levels rise and 1,25D serum concentrations decrease to diminish phosphate absorption further on (68). The decline of 1,25D due to elevated FGF23 is prolonged via suppression of renal 1α-hydroxylase, the enzyme that catalyzes the synthesis of 1,25D from the major circulating metabolite 25OHD, as well as induction of 24-hydroxylase, the enzyme responsible for production of 24,25(OH)2D3 (69). Thus, reduction of intestinal calcium absorption due to decreased 1,25D levels in conjunction with low ionized calcium leading to pronounced increase of PTH level and ultimately in secondary hyperparathyroidism.

Thus, alterations to levels of FGF23, which progressively increase together with changes in the metabolism of phosphate, calcium, PTH and/or 1,25D in worsening renal dysfunction with CKD result in CKD-MBD. This complex clinical syndrome is characterized by abnormalities in bone and mineral metabolism as well as extra-skeletal calcification resulting in fractures and bone deformities and, most prominently, in poor growth (10, 70), which all of them contribute to enhanced risk of CVD, fractures and mortality across all stages of CKD. The pathogenesis of CKD-MBD is complex, involving regulatory mechanism in bone, kidney, heart and parathyroid glands.

**FGF23 AND LVH IN CKD**

In early CKD, circulating FGF23 levels rise exponentially and are up-to 1,000-fold enhanced in kidney failure (65, 66). Elevated FGF23 levels are associated with all-cause and CV mortality in the general population (71, 72) as well as in CKD patients (73), LV dysfunction and atrial fibrillation (AF) in patients without CV co-morbidities (74, 75), and the development of cardiac hypertrophy (76) and fibrosis (77). Thereby, cardiac remodeling was shown to be stimulated by activation of myocardial FGFR4 although
FIGURE 1 | Pathological effects of FGF23 in CKD on the kidney and heart. Chronically high phosphate load and hypersecretion of parathyroid hormone (PTH) stimulate the synthesis of fibroblast growth factor (FGF) 23 in the bone. Increased level of circulating FGF23 activates FGF receptor (FGFR) 1/Klotho complex in the kidney leading to decreased expression of sodium phosphate transporters NaPi2a and NaPi2c enhancing phosphate (P) excretion. FGF23 further suppresses 1α-hydroxylase and increases 24-hydroxylase resulting in reduced serum 1,25D level. Acting on the heart, FGF23 activates FGFR4 independent of Klotho that induces pro-hypertrophic signaling pathways promoting the development of left ventricular hypertrophy (This figure is created with BioRender.com).

independent of α-Klotho (Figure 1) (78, 79). Higher FGF23 levels were further observed in stable ischaemic cardiomyopathy (72) and heart failure (HF) with reduced ejection fraction (HFrEF) (80–82).

The role of FGF23 in the development of LVH in children with CKD was investigated intensively since the last decade. Thereby it was shown that FGF23 level are markedly increased in haemodialysis patients with prevalent concentric LVH (66, 83), while in a study cohort of 83 children with non-dialysis stages 3–5 CKD no significant relationship between circulating FGF23 and LVH was observed (84). However, the Chronic Kidney Disease in Children (CKiD) study enrolled children with mild-to-moderate pre-dialysis CKD, respectively, concluded that a high plasma FGF23 concentration above 170 RU/ml together with estimated GFR ≥ 45 ml/min per 1.73 m$^2$ is associated with a higher prevalence of LVH (85, 86). Importantly, these studies differ in methods and number of enrolled children. Sinha et al. measured serum intact FGF23 in 83 children, whereas Portale et al. and Mitsnefes et al. measured C-terminal FGF23 plasma level in 419 and 587 children, respectively. This is controversial, since on the one hand intact FGF23 level are varying with a diurnal rhythm and have a high intraindividual variation (87). Furthermore, carefully handling is needed when processing K2-EDTA plasma, otherwise intact FGF23 will be unstable (88). On the other hand, intact FGF23 may reflect the biological relevance more than C-terminal FGF23 does (89). There is evidence, that the active full-length form is counter-regulated by the C-terminal fragments (90). Also, it was shown that the effect of dietary phosphate restriction on FGF23 has a greater impact on intact FGF23 than on the C-terminal form (91). The situation is complicated further by the fact that the four commercially available FGF23 assays are not validated for clinical use and are not standardized (92, 93).

Mechanistically, it was shown that FGF23 directly induces hypertrophic growth of cardiac myocytes in vitro and cardiac hypertrophy in vivo that was abolished by inhibition of phospholipase Cy (PLCy) or calcineurin, but not by the use of MAP kinase, PI3 kinase or Akt inhibitors. Also, the use of PD173074 to block all FGFRs reduced LV mass and the cardiac expression of genes associated with LVH (94). A few years later, FGFR4 was identified to be the main effector of FGF23 signaling in the heart (78) leading to the conclusion that cardiac hypertrophy induced by FGF23 is mediated by the FGFR4/PLCy/calcineurin pathway that activate nuclear factor of activated T-cells (NFAT) and consequently pro-hypertrophic NFAT target genes (Figure 2). A second mode of action for FGF23’s pro-hypertrophic properties could be the direct regulation of the sodium-chloride channel NCC in distal renal tubules by FGF23 rendering it to be a sodium-conserving hormone (95). A connection of FGF23, cardiac hypertrophy and the local RAAS in the heart is also discussed. In 5/6 nephrectomised rats as experimental model of uraemia, an increase in size of myocyte as well as enhanced cardiac fibrosis together with induction of cardiac Fgf23 and RAAS-associated gene expression was overserved (23). Paricalcitol mediated downregulation of RAAS and NFAT, respectively, together with diminished FGF23 level could thus attenuate cardiac hypertrophy (96, 97). In a retrospective case–control study in 24 pediatric CKD patients with kidney failure the relevance of FGF23 on cardiac fibrosis was evaluated (98).
FGF23 and LVH in CKD

**FIGURE 2** | FGF23 signaling in cardiac myocytes. Fibroblast growth factor (FGF) 23 binds to FGF receptor (FGFR) 4 in cardiac myocytes that results in phosphorylation of phospholipase Cγ (PLCγ). The PLCγ-mediated activation of calcineurin dephosphorylates nuclear factor of activated T-cells (NFAT) that translocates into the nucleus and induces pro-hypertrophic target genes involved in cardiac remodeling (This figure is created with BioRender.com).

collagen type I and III together with enhanced expression of pro-fibrotic growth factors and components of RAAS were observed, leading to the conclusion that FGF23 is induced by activated RAAS thereby promoting cardiac fibrosis. *In vitro*, FGF23-induced hypertrophic growth of isolated neonatal rat ventricular myocytes (NRVM) could be reversed by incubation with cyclosporine A, losartan and spironolactone. Furthermore, FGF23-mediated induction of TGF-β and CTGF in neonatal cardiac fibroblasts (NRCF) could be suppressed by losartan and spironolactone. Thus, leading to the conclusion that beside FGFR4/PLCγ/calcineurin signaling pathway, FGF23 promotes cardiac hypertrophy and fibrosis via activation of intra-cardiac RAAS.

During LVH, cardiac *Fgf23* expression is higher in cardiomyocyte-specific calcineurin A transgenic mice with normal *Fgf23* mRNA levels in bone. This phenomenon was also observed in an animal model as well as in humans with myocardial infarction, indicating that an intra-cardiac synthesis of FGF23 may trigger a pathological cardiac phenotype in a paracrine manner. The latter is in line with a study in myocardial autopsy samples of pediatric patients with kidney failure showing in association of high cardiac FGF23 expression with LVH. Moreover, Leifheit-Nestler and Grabner et al. postulate in addition to FGF23 that the upregulation of FGFR4 in the myocardium of uremic rats further contributes to the development of LVH. Paradoxically, different mouse models of X-linked hypophosphatemia (XLH) as well as patients with XLH develop no cardiac hypertrophy although presenting high FGF23 level. The different clinical phenotype of XLH with its low serum phosphate and calcium level, normal renal function and no signs of atherosclerosis could be an explanation for those findings. Interestingly, a recent study in mice showed that a conditional deletion of *Fgf23* in late osteoblast/osteocyte (*Fgf23fl/fl*Dmp1-Cre⁺) followed by inducing CKD using an adenine-containing diet did not prevent hyperparathyroidism. Rather increased phosphate level as well as more pronounced cardiac hypertrophy were observed compared to uremic controls leading the authors to the conclusion that elevated FGF23 level in CKD may have a protective role to maintain cardiac homeostasis. Taken together, both the latter study and the studies in XLH conclude that phosphate may be a key mineral for FGF23 to exert its cardiotoxicity. However, further studies need to investigate the relationship between high FGF23 levels and altered phosphate homeostasis.

Cardiac hypertrophy is often accompanied by myocardial fibrosis, an excessive proliferation of fibroblast resulting in stiffening of cardiac tissue thereby giving resistance to pressure overload, but also stimulating diastolic dysfunction. FGF23 was recently discovered to be involved in the development of cardiac fibrosis. In a rat model of cardiac hypertrophy by pulmonary artery banding, FGF23 expression was highly upregulated in cardiac myocytes. Myocytes then secreted FGF23 to promote the activation of fibroblasts together with TGF-β1 and to transform fibroblasts into myofibroblasts via FGFR1. Finally, FGF23 levels correlated with fibrosis in heart failure patients with preserved ejection fraction (HFpEF). However, the expression of cardiac FGF23 did not correlate with the amount of cardiac fibrosis in pediatric patients with kidney failure. Thus, the impact of FGF23 on the development of cardiac fibrosis has to be investigated in future studies in more detail.
FIGURE 3 [Investigated strategies targeting the FGF23-αKlotho-axis to ameliorate uremic cardiomyopathy. Dietary phosphate restriction causes a reduction in circulating levels of fibroblast growth factor (FGF) 23, while the use of phosphate binders or nicotinamide do not. Patients with chronic kidney disease (CKD) receiving calcimimetics show lower circulating FGF23 levels associated with reduced cardiovascular death and heart failure. Calcitriol therapy in 5/6 nephrectomized rats causes less activation of the FGF23/FGF receptor (FGFR) 4/calcinurin/nuclear factor of activated T-cells (NFAT) signaling pathway and improved left ventricular hypertrophy (LVH). However, treatment with active vitamin D shows no improvement of cardiac phenotype. The use of FGF23 neutralizing antibodies in uremic rats leads to decreased parathyroid hormone (PTH) levels and increased vitamin D, but causes aortic calcification and enhanced mortality. In contrast, targeting FGFR4 using anti-FGFR4 neutralizing antibodies attenuated LVH in vivo and inhibits FGF23-induced cardiac myocyte hypertrophy in vitro. Treatment with recombinant αKlotho reduces uremic cardiac remodeling without affecting high FGF23 levels (This figure is created with BioRender.com).

THERAPEUTIC APPROACHES TO REDUCE FGF23’S CV COMORBIDITIES

The aim of any therapeutic approach in pediatric CKD is to delay the progression of kidney failure and to improve CVD outcomes. FGF23 is associated with adverse CV outcome in CKD-MBD and it is thought to be a promising biomarker and a target for future therapeutic approaches. One of the most important studies that directly targeted FGF23 by using anti-FGF23 antibodies failed to improve the CV outcome in uremic rats and even increased mortality due to high phosphate-mediated vascular calcifications (Figure 3) (109). Whether therapeutic use of anti-FGF23 antibodies in dialysis patients, relieved of chronic phosphate load by dialysis, is more effective in reducing cardiac remodeling remains an open question.

Several studies target dietary phosphate restriction to lower FGF23 levels (Figure 3). Thereby, dietary phosphate restriction in healthy participants resulted in decreased intact FGF23 level, whereas phosphate-enriched diets increased intact FGF23 (110). The same findings were observed in studies of CKD and phosphate-restricted vs. phosphate-enriched diets (111, 112). However, it was further reported that C-terminal FGF23 was not changed regardless of the dietary phosphate content (113, 114). A recently published randomized clinical trial in stage 3b/4 CKD patients, the CKD Optimal Management with Binders and Nicotinamide (COMBINE) study, hypothesized that lowering phosphate level in early CKD prevents rising level of FGF23 and with that FGF23-associated morbidity and mortality (Figure 3). However, a 12 months therapy with lanthanum carbonate and/or nicotinamide failed to lower serum phosphate and FGF23 levels (115). The same was observed in other studies (116–118). Calcimimetics turned out to be more effective in lowering FGF23 and with that lowering mortality and CVD events significantly in patients with kidney failure (Figure 3) (119). However, further studies need to confirm the promising beneficial use of...
calcimimetics on cardiac function in the future and to elucidate the exact molecular mechanisms of its possible cardioprotection.

Further studies included the treatment of vitamin D deficiency in 5/6 nephrectomized rats with calcitriol that reduced the expression of FGF23 and FGF4 in the heart inactivating calcineurin/NFAT signaling and thereby reduced the development of LVH (102). However, active vitamin D treatment failed to improve LVH in pediatric CKD patients (Figure 3) (120). Targeting FGFR4 with neutralizing antibodies attenuated LVH in animal models of CKD or high phosphate load by reducing cardiac remodeling without affecting FGF23 level (78). However, clinical studies on the therapeutic benefit of anti-FGFR4 antibodies in LVH are still pending. Treatment of uremic cardiomyopathy in rodents with recombinant αKlotho ameliorated LVH and fibrosis independent of high FGF23 synthesis (Figure 3), but again, clinical studies are lacking to prove the positive effects of Klotho therapy on the CV system (121).

Currently, FGF23 concentrations are not routinely measured in patients. One reason is the absence of reliable immunoassays for measurement of FGF23, which are validated for clinical use (93, 122). Another reason is the reduced stability of biologically active intact FGF23 when blood processing is delayed (123), thus making it difficult to apply its use in routine clinical work. It remains questionable if FGF23 is a good predictor for progression of CKD. So far, only one study in adults with CKD has shown a benefit of adding FGF23 to existing prediction models for CKD progression (124), whereas all other studies have thus far failed to show any advantage in risk prediction for CKD onset when including FGF23 (125–127). Nevertheless, for the prediction of all-cause mortality in CKD patients, FGF23 seems to be a better prognostic marker (125, 128). Regarding CV outcomes, studies remain inconsistent. Alderson et al. point toward FGF23 to be a good predictor of CV events in pre-dialysis patients (128). Besides, Emrich et al. suggest that inclusion of NT-proBNP into the prediction model eliminates the association between FGF23 level and CV outcome (129). However, there is evidence that measured FGF23 levels can nevertheless predict the accessibility of patients to certain therapeutic approaches as shown for the treatment of patients with e.g., stable ischemic heart disease with angiotensin-converting enzyme inhibitor (130).

Experimental and clinical data reviewed here suggest it remains reasonable to consider that reducing elevated level of FGF23 is potentially a promising therapeutic pathway for reducing CVD in CKD in adult and children. Randomized clinical trials targeting the pathophysiology of FGF23-induced CVD are needed to help clarify the impact of FGF23 on LVH in CKD.

CONCLUSION

In summary, the scientific community gained a lot of knowledge about the regulation and effects of FGF23. Although FGF23 mainly regulates phosphate homeostasis, in adults as well as in pediatric CKD the levels of FGF23 are markedly increased with progressing kidney failure and high FGF23 levels are strongly associated with left ventricular hypertrophy. However, a direct link to other CKD associated CV abnormalities needs to be proven in pediatric patients. In fact, CV events e.g., cardiac arrest and arrhythmia, are the leading cause of death in children with CKD and a dysregulated FGF23 metabolism may additionally have detrimental effects on the cardiovascular system. Regardless, many findings are contradictory and large prospective clinical studies are needed to elucidate the exact pathological mechanisms of FGF23 induced CVDs in pediatric CKD.

AUTHOR CONTRIBUTIONS

AG performed literature research, drafted the manuscript, and designed the figures. MS critically discussed content of review and all revisions of the manuscript. DH critically discussed the content of the review and revised the manuscript. ML-N designed the figures. AG performed literature research, drafted the manuscript, and revised the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Levey AS, Coresh J, Bolton K, Cullerton B, Harvey KS, Ikizler TA, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. (2002) 39:S1–S66.
2. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. JASN. (2015) 26:2504–11. doi: 10.1681/ASN.2014070714
3. Clementi A, Virizi GM, Goh CY, Cruz DN, Granata A, Vescovo G, et al. Cardiorenal syndrome type 4: a review. Cardiorenal Med. (2013) 3:63–70. doi: 10.1159/000350397
4. Granata A, Clementi A, Virizi GM, Brocca A, Cal M de, Scarfia VR, et al. Cardiorenal syndrome type 4: from chronic kidney disease to cardiovascular impairment. Eur J Intern Med. (2016) 30:1–6. doi: 10.1016/j.ejim.2016.02.019
5. Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. Pathophysiology of the cardio-renal syndromes types 1–5: an up-to-date. Indian Heart J. (2017) 69:255–65. doi: 10.1016/j.ijhj.2017.01.005
6. Himmelfarb J, Ikizler TA. Hemodialysis. New Engl J Med. (2010) 363:1833–45. doi: 10.1056/NEJMrat902710
7. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. New Engl J Med. (2004) 350:2654–62. doi: 10.1056/NEJMoat031643
8. Groothoff JW, Gruppen MP, Offringa M, Hutton J, Lilien MR, van de Kar NJ, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int. (2002) 61:621–9. doi: 10.1046/j.1523-1755.2002.00156.x
9. Kouri AM, Rheault MN. Cardiovascular disease in children with chronic kidney disease. Curr Opin Nephrol Hyp. (2021) 30:231–6. doi: 10.1097/MNH.0000000000000684
10. Moe S, Drücke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. (2006) 69:1945–53. doi: 10.1016/j.kint.200508041
11. Matteucci MC, Wähü E, Picca S, Mastrostefano A, Rinelli G, Romano C, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. JASN. (2006) 17:218–26. doi: 10.1681/ASN.2005030276
12. Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. JASN. (2010) 21:137–44. doi: 10.1067/masn.2009090430.
13. Sinha MD, Tibby SM, Rasmussen P, Rawlins D, Turner C, Dalton RN, et al. Blood pressure control and left ventricular mass in children with chronic kidney disease. CJASN. (2011) 6:543–51. doi: 10.2215/CIN.04690510

14. Doyon A, Haas P, Erdem S, Ranchin B, Kassai B, Mancarelli F, et al. Impaired systolic and diastolic left ventricular function in children with chronic kidney disease - results from the 4C study. Cr. Sci. Rep. (2019) 9:11462. doi: 10.1038/s41598-019-46653-3

15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré LG, et al. Inflammation-related mechanisms in chronic kidney disease - effects from the 4C study. Clin Exp Nephrol. (2015) 19:615–23. doi: 10.1007/s10654-015-2705-3

16. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell. Bio. (2005) 6:589–600. doi: 10.1038/nrm1570

17. Guo H, Sinha MD, Li Y, Simpson J, Chowienczyk PJ. Elevated ejection-phase myocardial wall stress in children with chronic kidney disease. Hypertension. (2015) 66:823–9. doi: 10.1161/HYPERTENSIONAHA.115.05704

18. Pitoulis FG, Terracciano CM. Heart plasticity in response to pressure- and volume-overload: a review of findings in compensated and decompensated phenotypes. Front. Physiol. (2020) 11:92. doi: 10.3389/fphys.2020.00092

19. Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clin Exp Nephrol. (2019) 23:85–98. doi: 10.1007/s10049-018-0610-1

20. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. (2002) 110:229–38. doi: 10.1172/JCI215219

21. Xiang W, Kong J, Chen S, Cao L-P, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. (2005) 288:E125–32. doi: 10.1152/ajpendo.00224.2004

22. Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol. (2018) 9:278. doi: 10.3389/fendo.2018.00278

23. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE. (2012) 7:e44161. doi: 10.1371/journal.pone.0044161

24. Prieto MC, González-Villalobos RA, Botros FT, Martin VL, Pagán J, Satro R, et al. Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. (2011) 300:F749–55. doi: 10.1152/ajprenal.00383.2009

25. Böckmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer D-C, et al. FGF23-mediated activation of local RAAs promotes cardiac hypertrophy and fibrosis. Int J Mol Sci. (2019) 20:4634. doi: 10.3390/ijms20184634

26. Song MA de, Mirkovic K, Menecke R, Hoenderop JG, Bindels BJ, Vervoort MG, et al. Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis. Nephrol Dial Transplant. (2017) 32:73–80. doi: 10.1093/ndt/gfw105

27. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in chronic kidney disease. CJASN. (2011) 6:521–30. doi: 10.2215/CIN.04690510

28. London GM, Marchais SJ, Gérin AP, Métivier F. Arteriosclerosis, vascular calcifications and cardiovascular disorders. J Am Coll Cardiol. (2005) 45:324–33. doi: 10.1016/j.jacc.2004.09.018

29. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiovasc Rev. (2014) 22:147–51. doi: 10.1097/CRD.000000000000021

30. Kamisaka J, Stopinski M, Mucha K, Jedrzejczak A, Golebiowski M, Niewczas MA, et al. IL-6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine. (2019) 1209–14. doi: 10.1016/j.cyto.2019.04.002

31. Gupta J, Dominic EA, Fink JC, Ojo AO, Barrows IR, Reilly MP, et al. Association between inflammation and cardiac geometry in chronic kidney disease: findings from the CRIC Study. PLoS ONE. (2015) 10:e0124772. doi: 10.1371/journal.pone.0124772

32. Chia S, Qidan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. (2003) 23:695–701. doi: 10.1161/01.ATV.0000065195.22904.FA

33. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. (2016) 90:985–96. doi: 10.1016/j.kint.2016.05.019

34. Gruppen MP, Groothoff JW, Prins M, van der Wouw P, Offringa M, Bos WJ, et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int. (2003) 63:1058–65. doi: 10.1046/j.1523-1755.2003.00814.x

35. Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. (2009) 54:345–60. doi: 10.1053/j.ajkd.2009.04.027

36. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. (2019) 79:365–79. doi: 10.1007/s40265-019-1064-1

37. Jackson RE, Bellamy MC. Antihypertensive drugs. BJ A Educ. (2015) 15:280–5. doi: 10.1093/bjaceaccp/mku061

38. Mitsnefes MM, Kimball TR, Kattal I, Witt SA, Glasscock BJ, Khoury PR, et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr. (2006) 149:671–5. doi: 10.1016/j.jpeds.2006.08.017

39. Schlüter K-D, Piper HM. Cardiovascular actions of parathormone and parathormone-related peptide. Cardiovasc Res. (1998) 37:34–41. doi: 10.1002/sor.63639(7)00194-6

40. Bakkaloglu SA, Borzych D, Soo Ha I, Serdaroglu E, Büscher R, Salas P, et al. Cardiac geometry in children receiving chronic peritoneal dialysis: findings from the International Pediatric Peritoneal Dialysis Network (IPPDN) registry. CJASN. (2011) 6:9196–33. doi: 10.2215/CJN.05990710

41. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. (1997) 52:668–72. doi: 10.1016/kiji.1997.354

42. Lilien MR, Koomans HA, Schröder CH. Hemodialysis acutely impairs endothelial function in children. Pediatr Nephrol. (2005) 20:200–4. doi: 10.1007/s00467-004-1718-3

43. Drozdz D, Kwipta P, Szefko K, Kordon Z, Drozdz T, Latka M, et al. Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxid Med Cell Longev. (2016) 2015:752031. doi: 10.1155/2016/752031

44. Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, et al. Dyslipidemia, carotid intima-media thickness and endothelial dysfunction...
in children with chronic kidney disease. *Pediatr Nephrol.* (2016) 31:1313–20. doi: 10.1007/s00467-016-3350-4

52. Goodman WG, Goldin J, Kuizion BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *New Engl J Med.* (2000) 342:1478–83. doi: 10.1056/NEJM200008243421302

53. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis.* (1998) 32:S112–9. doi: 10.1053/ajkd.1998.s3.e9820470

54. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. *Circulation.* (2011) 123:1650–60. doi: 10.1161/CIRCULATIONAHA.110.007021

55. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. *Circulation.* (2011) 123:1990–10. doi: 10.1161/CIRCULATIONAHA.110.009118

56. Sanchis P, Ho CY, Liu Y, Beltran LE, Ahmad S, Jacob AP, et al. Arterial “inflammaging” drives vascular calcification in children on dialysis. *Kidney Int.* (2019) 95:958–72. doi: 10.1016/j.kint.2018.12.014

57. Shroff RC, Donald AE, Hoorn MS, Watson A, Feather S, Milford D, et al. Mineral metabolism and vascular damage in children on dialysis. *JASN.* (2007) 18:2996–3003. doi: 10.1681/ASN.2006121397

58. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in young adults with end-stage renal disease, vascular disease, and aging: part 1 of a 2-part review. *Am J Kidney Dis.* (1998) 32:S112–9. doi: 10.1053/ajkd.1998.s3.e9820470

59. Ix JH, Katz R, Kestenbaum BR, Boer IH de, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). *J Am Coll Cardiol.* (2012) 60:2600–7. doi: 10.1016/j.jacc.2012.03.040

60. Lutssey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities Study. *J Am Heart Assoc.* (2014) 3:e000936. doi: 10.1161/JAHA.114.000936

61. Mehta R, Cai X, Lee J, Scialla JI, Bansal N, Sondheimer JH, et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. *JAMA Cardiology.* (2016) 1:548–56. doi: 10.1001/jamacardio.2016.1445

62. Seiler S, Cremers B, Reblig NM, Hornof F, Jeken J, Kersting S, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. *Eur Heart J.* (2011) 32:2688–96. doi: 10.1093/eurheartj/ehr215

63. Chua W, Purmay H, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. *Eur Heart J.* (2019) 40:1268–76. doi: 10.1093/eurheartj/ehr815

64. Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. *JCI.* (2011) 121:4393–408. doi: 10.1172/JCI46122

65. Grabner A, Schramm K, Silwal N, Hendrix M, Yanuci C, Czayka B, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. *Sci Rep.* (2017) 7:1993. doi: 10.1038/s41598-017-02068-6

66. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanuci C, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. *Cell Metab.* (2015) 22:1020–32. doi: 10.1016/j.cmet.2015.09.002

67. Leifheit-Nestler M, Große Siemer R, Flasbart K, Kirchhoff F, Ziegler FH, et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis. *ESC Heart Fail.* (2019) 6:356–44. doi: 10.1002/euhf.12416

68. Seherunwong V, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and incident coronary heart disease, heart failure, and reduced ejection fraction. *Circ Heart Fail.* (2015) 8:1059–67. doi: 10.1161/CIRCHEARTFAILURE.115.002341

69. Plischke M, Neuhold S, Adlibrecht C, Bielesz B, Shayganfar S, Bieglemayer C, et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. *Eur J Clin Invest.* (2012) 42:649–56. doi: 10.1111/j.1365-2362.2011.02631.x

70. Jeisnen B von, Sopova K, Palapies L, Leistner DM, Fichtlscherer S, Seeger FH, et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis. *ESC Heart Fail.* (2019) 1:653–46. doi: 10.1002/euhf.12416

71. Sinha MD, Turner C, Booth CJ, Waller S, Rasmussen P, Goldsmith DJ, et al. Relationship of FGF23 to indexed left ventricular mass in children with CKD. *CJASN.* (2018) 13:45–52. doi: 10.2215/CJN.01210517

72. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. *CJASN.* (2014) 9:344–53. doi: 10.2215/CJN.0840513

73. Saito H, Maeda A, Ohtomo S-I, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. *J Biol Chem.* (2005) 280:2543–9. doi: 10.1074/jbc.M408932200

74. Portale AA, Booth BE, Halloran BP, Morris RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. *Eur J Clin Invest.* (1984) 14:7580–9. doi: 10.1111/j.1365-2362.2011.02631.x

75. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgfs3 demonstrates an essential physiological role of Fgfs3 in phosphat and vitamin D metabolism. *J Clin Invest.* (2004) 113:561–8. doi: 10.1172/JCI111365

76. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, et al. Fracture burden and risk factors in childhood CKD: results from the CKID Cohort Study, *JASN.* (2016) 27:543–50. doi: 10.1681/ASN.2015020152

77. Ix JH, Katz R, Kestenbaum BR, Boer IH de, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular risks in communities study. *Clin Chim Acta.* (2011) 412:1008–11. doi: 10.1016/j.cca.2011.02.009
90. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. *PNAS*. (2010) 107:407–12. doi: 10.1073/pnas.0902061107

91. Tsai W-C, Wu H-Y, Peng Y-S, Hsu S-P, Chiu Y-L, Chen H-Y, et al. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis. *Nephrol Dial Transplant*. (2018) 33:1977–83. doi: 10.1093/ndt/gfy005

92. Bouma-de Krijger A, Vervloet MG. Fibroblast growth factor 23: are we ready to use it in clinical practice? *J Nephrol*. (2020) 33:509–27. doi: 10.1007/s40620-020-00715-2

93. Smith ER, McMahon LP, Holt SG. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. *Clin Chem Lab Med*. (2013) 51:1971–81. doi: 10.1515/ccl-2013-0208

94. Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, et al. Treatment of established left ventricular hypertrophy with fibroblist growth factor receptor blockade in an animal model of CKD. *Nephrol Dial Transplant*. (2014) 29:2028–35. doi: 10.1093/ndt/gfu190

95. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shallhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. *EMBO Mol Med*. (2014) 6:744–59. doi: 10.1002/emmm.201303716

96. Czaya B, Seeherunvong W, Singh S, Yanucil C, Ruiz P, Quiroz Y, et al. Cardioprotective effects of paricalcitol alone and in combination with FGF23 receptor inhibition in chronic renal failure: experimental and clinical studies. *Am J Hypertens*. (2019) 32:34–44. doi: 10.1016/j.ajh.19p/154

97. Freundlich M, Li YC, Quiroz Y, Bravo Y, Seeherunvong W, Faul C, et al. Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. *Am J Hypertens*. (2014) 27:720–6. doi: 10.1016/j.amjhyt.177

98. Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetj e B, Klintschar M, et al. FGF23 and cardiovascular disease. *Kidney Int*. (2015) 87:1831–9. doi: 10.1016/j.kint.2015.06.007

99. Matsui I, Oka T, Kusunoki Y, Mori D, Hashimoto N, Matsumoto A, et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor-23 levels in CKD. *J Nephrol*. (2011) 46:83–9. doi: 10.1093/ndt/gfu190

100. Roy C, Lejeune S, Slimani A, Meester C de, Ahn AS SA, Rousseau M, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. *J Clin Invest*. (2012) 122:2543–53. doi: 10.1172/JCI61405

101. Tanaka Y, Kusakari Y, Usugi K, Samba K, Urashima T, Akaite T, et al. FGF23: a biomarker of fibrosis for cardiac fibrosis in the presence of transforming growth factor-β1. *PloS ONE*. (2020) 15:e0231905. doi: 10.1371/journal.pone.0231905

102. Clinkenbeard EL, Noonan ML, Thomas JC, Ni P, Hum JM, Aref M, et al. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. *JCI Insight*. (2019) 4:e123817. doi: 10.1172/jci.insight.123817

103. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. *PNAS*. (2010) 107:407–12. doi: 10.1073/pnas.0902061107

104. Liu ES, Thoonen R, Petit E, Yu B, Buijs ES, Scherrer-Crosbie M, et al. Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor receptor blockade in an animal model of CKD. *Nephrol Dial Transplant*. (2014) 29:2028–35. doi: 10.1093/ndt/gfu190

105. Pastor-Arroyo E-M, Gehring N, Krudewig C, Costantino S, Bettoni C, Knopfel T, et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. *Kidney Int*. (2018) 94:49–59. doi: 10.1016/j.kint.2018.02.017

106. Clinkenbeard EL, Noonan ML, Thomas JC, Ni P, Hum JM, Aref M, et al. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. *JCI Insight*. (2019) 4:e123817. doi: 10.1172/jci.insight.123817
124. Smith ER, Ford ML, Tomlinson LA, McMahon LP, Rajkumar C, Holt SG. FGF23 adds value to risk prediction in patients with chronic kidney disease. Bone. (2012) 51:830–1; author reply 832–3. doi: 10.1016/j.bone.2012.05.017

125. Edmonston D, Wojdyla D, Mehta R, Cai X, Lora C, Cohen D, et al. Single measurements of carboxy-terminal fibroblast growth factor 23 and clinical risk prediction of adverse outcomes in CKD. Am J Kidney Dis. (2019) 74:771–81. doi: 10.1053/j.ajkd.2019.05.026

126. Artunc F, Nowak A, Müller C, Peter A, Heyne N, Häring H-U, et al. Mortality prediction using modern peptide biomarkers in hemodialysis patients—a comparative analysis. Kidney Blood Press Res. (2014) 39:563–72. doi: 10.1159/000368468

127. Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. (2018) 93:1198–206. doi: 10.1016/j.kint.2017.11.024

128. Alderson HV, Ritchie JP, Middleton R, Larsson A, Larsson TE, Kalra PA. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5. Nephrology. (2016) 21:566–73. doi: 10.1111/nep.12664

129. Emrich IE, Brandenburg V, Sellier AB, Schauerte J, Wiedenroth J, Untersteller K, et al. Strength of fibroblast growth factor 23 as a cardiovascular risk predictor in chronic kidney disease weaken by ProBNP adjustment. Am J Nephrol. (2019) 49:203–11. doi: 10.1159/000497125

130. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. (2014) 63:2421–8. doi: 10.1016/j.jacc.2014.03.026

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Grund, Sinha, Haffner and Leifheit-Nestler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.